Lixte Biotechnology shares are trading lower after the company announced pricing of a $3.5 million registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules.
Portfolio Pulse from Benzinga Newsdesk
Lixte Biotechnology has announced the pricing of a $3.5 million registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules. This has led to a decrease in the company's share price.
July 18, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lixte Biotechnology's stock price is trading lower after the company announced a $3.5 million registered direct offering and concurrent private placement.
The announcement of a registered direct offering and concurrent private placement often leads to a decrease in a company's share price as it dilutes the value of existing shares. This is the case for Lixte Biotechnology, which has seen its share price decrease following the announcement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100